Richard Heyman, Ph.D.

Dr. Heyman was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, biotech companies focused on therapeutics targeting hormone-dependent cancers. Johnson & Johnson acquired Aragon in 2013 and GenentechRoche purchased Seragon in 2014. He currently serves on the boards of Enliven, ORIC Pharmaceuticals, PMV Pharma, and Vividion Therapeutics. He is vice chairman of The Salk Institute.

  • March 2023

Added to: RayzeBio Inc. - San Diego, CA

RayeBio is a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets.